{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T20:14:39Z","timestamp":1790972079057,"version":"4.1.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,3,10]],"date-time":"2022-03-10T00:00:00Z","timestamp":1646870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,3,10]],"date-time":"2022-03-10T00:00:00Z","timestamp":1646870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s11912-022-01240-0","type":"journal-article","created":{"date-parts":[[2022,3,10]],"date-time":"2022-03-10T06:02:47Z","timestamp":1646892167000},"page":"741-749","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Rehabilitation Needs for Patients Undergoing CAR T-Cell Therapy"],"prefix":"10.1007","volume":"24","author":[{"given":"Obada","family":"Obaisi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhodora C.","family":"Fontillas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krina","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4797-4147","authenticated-orcid":false,"given":"An","family":"Ngo-Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,10]]},"reference":[{"issue":"1","key":"1240_CR1","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","volume":"379","author":"CH June","year":"2018","unstructured":"June CH, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med. 2018;379(1):64\u201373.","journal-title":"N Engl J Med"},{"issue":"8","key":"1240_CR2","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s11912-020-00935-6","volume":"22","author":"K Landry","year":"2020","unstructured":"Landry K, Thomas AA. Neurological complications of CAR T cell therapy. Curr Oncol Rep. 2020;22(8):83.","journal-title":"Curr Oncol Rep"},{"issue":"4","key":"1240_CR3","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1007\/s00415-020-10237-3","volume":"268","author":"EC Tallantyre","year":"2021","unstructured":"Tallantyre EC, Evans NA, Parry-Jones J, Morgan MPG, Jones CH, Ingram W. Neurological updates: neurological complications of CAR-T therapy. J Neurol. 2021;268(4):1544\u201354.","journal-title":"J Neurol"},{"issue":"4","key":"1240_CR4","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.ncl.2020.08.001","volume":"38","author":"MW Ruff","year":"2020","unstructured":"Ruff MW, Siegler EL, Kenderian SS. A concise review of neurologic complications associated with chimeric antigen receptor T-cell immunotherapy. Neurol Clin. 2020;38(4):953\u201363.","journal-title":"Neurol Clin"},{"issue":"Suppl 1","key":"1240_CR5","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1002\/hon.2591","volume":"37","author":"D Sermer","year":"2019","unstructured":"Sermer D, Brentjens R. CAR T-cell therapy: full speed ahead. Hematol Oncol. 2019;37(Suppl 1):95\u2013100.","journal-title":"Hematol Oncol"},{"key":"1240_CR6","unstructured":"Society AC. CAR T-cell therapy and its side effects [Available from: https:\/\/www.cancer.org\/treatment\/treatments-and-side-effects\/treatment-types\/immunotherapy\/car-t-cell1.html.\u00a0Accessed 1 Oct 2021."},{"key":"1240_CR7","unstructured":"Society LaL. Chimeric antigen receptor (CAR) T-cell therapy [Available from: https:\/\/www.lls.org\/treatment\/types-treatment\/immunotherapy\/chimeric-antigen-receptor-car-t-cell-therapy.\u00a0Accessed 1 Oct 2021"},{"key":"1240_CR8","doi-asserted-by":"crossref","unstructured":"Myers GD, Verneris MR, Goy A, Maziarz RT. Perspectives on outpatient administration of CAR-T cell therapy in aggressive B-cell lymphoma and acute lymphoblastic leukemia. J Immunother Cancer. 2021;9(4):1-10.","DOI":"10.1136\/jitc-2020-002056"},{"issue":"Suppl 1","key":"1240_CR9","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/hon.2595","volume":"37","author":"SS Neelapu","year":"2019","unstructured":"Neelapu SS. Managing the toxicities of CAR T-cell therapy. Hematol Oncol. 2019;37(Suppl 1):48\u201352.","journal-title":"Hematol Oncol"},{"issue":"2","key":"1240_CR10","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","volume":"124","author":"DW Lee","year":"2014","unstructured":"Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124(2):188\u201395.","journal-title":"Blood"},{"issue":"1","key":"1240_CR11","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.annonc.2020.10.478","volume":"32","author":"ML Schubert","year":"2021","unstructured":"Schubert ML, Schmitt M, Wang L, Ramos CA, Jordan K, M\u00fcller-Tidow C, et al. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. Ann Oncol. 2021;32(1):34\u201348.","journal-title":"Ann Oncol"},{"issue":"1","key":"1240_CR12","first-page":"56","volume":"6","author":"A Shimabukuro-Vornhagen","year":"2018","unstructured":"Shimabukuro-Vornhagen A, G\u00f6del P, Subklewe M, Stemmler HJ, Schl\u00f6\u00dfer HA, Schlaak M, et al. Cytokine release syndrome. J Immunother. Cancer. 2018;6(1):56.","journal-title":"Cancer"},{"issue":"4","key":"1240_CR13","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with ummune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625\u201338.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"16","key":"1240_CR14","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507\u201317.","journal-title":"N Engl J Med"},{"issue":"3","key":"1240_CR15","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1097\/PPO.0000000000000377","volume":"25","author":"I Varadarajan","year":"2019","unstructured":"Varadarajan I, Lee DW. Management of T-cell engaging immunotherapy complications. Cancer J. 2019;25(3):223\u201330.","journal-title":"Cancer J"},{"issue":"7","key":"1240_CR16","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1093\/jnci\/djz017","volume":"111","author":"BD Hunter","year":"2019","unstructured":"Hunter BD, Jacobson CA. CAR T-cell associated neurotoxicity: mechanisms, clinicopathologic correlates, and future directions. J Natl Cancer Inst. 2019;111(7):646\u201354.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"1240_CR17","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","volume":"15","author":"SS Neelapu","year":"2018","unstructured":"Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15(1):47\u201362.","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"1240_CR18","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1182\/blood-2018-05-846428","volume":"132","author":"A Nellan","year":"2018","unstructured":"Nellan A, McCully CML, Cruz Garcia R, Jayaprakash N, Widemann BC, Lee DW, et al. Improved CNS exposure to tocilizumab after cerebrospinal fluid compared to intravenous administration in rhesus macaques. Blood. 2018;132(6):662\u20136.","journal-title":"Blood"},{"issue":"26","key":"1240_CR19","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531\u201344.","journal-title":"N Engl J Med"},{"issue":"6","key":"1240_CR20","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1002\/cam4.3664","volume":"10","author":"AI Hoogland","year":"2021","unstructured":"Hoogland AI, Jayani RV, Collier A, Irizarry-Arroyo N, Rodriguez Y, Jain MD, et al. Acute patient-reported outcomes in B-cell malignancies treated with axicabtagene ciloleucel. Cancer Med. 2021;10(6):1936\u201343.","journal-title":"Cancer Med"},{"key":"1240_CR21","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1182\/blood-2019-121715","volume":"134","author":"S Sidana","year":"2019","unstructured":"Sidana S, Thanarajasingam G, Griffin J, Thompson CA, Burtis M, Warsame R, et al. Patient experience of chimeric antigen receptor (CAR)-T cell therapy vs. stem cell transplant: longitudinal patient reported adverse events, cognition and quality of life. Blood. 2019;134:794.","journal-title":"Blood"},{"issue":"3","key":"1240_CR22","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1080\/17474086.2019.1585238","volume":"12","author":"UH Acharya","year":"2019","unstructured":"Acharya UH, Dhawale T, Yun S, Jacobson CA, Chavez JC, Ramos JD, et al. Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy. Expert Rev Hematol. 2019;12(3):195\u2013205.","journal-title":"Expert Rev Hematol"},{"issue":"3","key":"1240_CR23","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1111\/ejh.12335","volume":"93","author":"S Oerlemans","year":"2014","unstructured":"Oerlemans S, Issa DE, van den Broek EC, Nijziel MR, Coebergh JW, Mols F, et al. Impact of therapy and disease-related symptoms on health-related quality of life in patients with follicular lymphoma: results of the population-based PHAROS-registry. Eur J Haematol. 2014;93(3):229\u201338.","journal-title":"Eur J Haematol"},{"issue":"9","key":"1240_CR24","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1007\/s00277-011-1274-4","volume":"90","author":"S Oerlemans","year":"2011","unstructured":"Oerlemans S, Mols F, Nijziel MR, Lybeert M, van de Poll-Franse LV. The impact of treatment, socio-demographic and clinical characteristics on health-related quality of life among Hodgkin\u2019s and non-Hodgkin\u2019s lymphoma survivors: a systematic review. Ann Hematol. 2011;90(9):993\u20131004.","journal-title":"Ann Hematol"},{"issue":"16","key":"1240_CR25","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.1002\/cncr.29427","volume":"121","author":"S Oerlemans","year":"2015","unstructured":"Oerlemans S, Nijziel MR, van de Poll-Franse LV. Age-related differences in quality of life among patients with diffuse large B-cell lymphoma. Cancer. 2015;121(16):2857\u20138.","journal-title":"Cancer"},{"issue":"3","key":"1240_CR26","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s00277-013-1881-3","volume":"93","author":"N Vermaete","year":"2014","unstructured":"Vermaete N, Wolter P, Verhoef G, Gosselink R. Physical activity and physical fitness in lymphoma patients before, during, and after chemotherapy: a prospective longitudinal study. Ann Hematol. 2014;93(3):411\u201324.","journal-title":"Ann Hematol"},{"issue":"4","key":"1240_CR27","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1177\/1534735418807555","volume":"17","author":"J Nakano","year":"2018","unstructured":"Nakano J, Hashizume K, Fukushima T, Ueno K, Matsuura E, Ikio Y, et al. Effects of aerobic and resistance exercises on physical symptoms in cancer patients: a meta-analysis. Integr Cancer Ther. 2018;17(4):1048\u201358.","journal-title":"Integr Cancer Ther"},{"issue":"6","key":"1240_CR28","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.ctrv.2013.01.001","volume":"39","author":"S Persoon","year":"2013","unstructured":"Persoon S, Kersten MJ, van der Weiden K, Buffart LM, Nollet F, Brug J, et al. Effects of exercise in patients treated with stem cell transplantation for a hematologic malignancy: a systematic review and meta-analysis. Cancer Treat Rev. 2013;39(6):682\u201390.","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"1240_CR29","doi-asserted-by":"publisher","first-page":"514","DOI":"10.2522\/ptj.20120181","volume":"93","author":"IE van Haren","year":"2013","unstructured":"van Haren IE, Timmerman H, Potting CM, Blijlevens NM, Staal JB, Nijhuis-van der Sanden MW. Physical exercise for patients undergoing hematopoietic stem cell transplantation: systematic review and meta-analyses of randomized controlled trials. Phys Ther. 2013;93(4):514\u201328.","journal-title":"Phys Ther"},{"key":"1240_CR30","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.critrevonc.2017.12.011","volume":"122","author":"S Oberoi","year":"2018","unstructured":"Oberoi S, Robinson PD, Cataudella D, Culos-Reed SN, Davis H, Duong N, et al. Physical activity reduces fatigue in patients with cancer and hematopoietic stem cell transplant recipients: a systematic review and meta-analysis of randomized trials. Crit Rev Oncol Hematol. 2018;122:52\u20139.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"8","key":"1240_CR31","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1007\/s00277-013-1689-1","volume":"92","author":"N Vermaete","year":"2013","unstructured":"Vermaete N, Wolter P, Verhoef G, Gosselink R. Physical activity, physical fitness and the effect of exercise training interventions in lymphoma patients: a systematic review. Ann Hematol. 2013;92(8):1007\u201321.","journal-title":"Ann Hematol"},{"issue":"3","key":"1240_CR32","doi-asserted-by":"publisher","first-page":"jrm00163","DOI":"10.2340\/16501977-2810","volume":"53","author":"B Amatya","year":"2021","unstructured":"Amatya B, Khan F, Lew TE, Dickinson M. Rehabilitation in patients with lymphoma: an overview of Systematic Reviews. J Rehabil Med. 2021;53(3):jrm00163.","journal-title":"J Rehabil Med"},{"issue":"27","key":"1240_CR33","doi-asserted-by":"publisher","first-page":"4605","DOI":"10.1200\/JCO.2008.20.0634","volume":"27","author":"KS Courneya","year":"2009","unstructured":"Courneya KS, Sellar CM, Stevinson C, McNeely ML, Peddle CJ, Friedenreich CM, et al. Randomized controlled trial of the effects of aerobic exercise on physical functioning and quality of life in lymphoma patients. J Clin Oncol. 2009;27(27):4605\u201312.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1240_CR34","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s00520-013-1927-z","volume":"22","author":"K Oechsle","year":"2014","unstructured":"Oechsle K, Aslan Z, Suesse Y, Jensen W, Bokemeyer C, de Wit M. Multimodal exercise training during myeloablative chemotherapy: a prospective randomized pilot trial. Support Care Cancer. 2014;22(1):63\u20139.","journal-title":"Support Care Cancer"},{"key":"1240_CR35","doi-asserted-by":"publisher","first-page":"577","DOI":"10.2147\/CIA.S198591","volume":"14","author":"K \u00c5hlund","year":"2019","unstructured":"\u00c5hlund K, Ekerstad N, B\u00e4ck M, Karlson BW, \u00d6berg B. Preserved physical fitness is associated with lower 1-year mortality in frail elderly patients with a severe comorbidity burden. Clin Interv Aging. 2019;14:577\u201386.","journal-title":"Clin Interv Aging"},{"issue":"7","key":"1240_CR36","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s11912-020-00932-9","volume":"22","author":"K Lee","year":"2020","unstructured":"Lee K, Zhou J, Norris MK, Chow C, Dieli-Conwright CM. Prehabilitative exercise for the enhancement of physical, psychosocial, and biological outcomes among patients diagnosed with cancer. Curr Oncol Rep. 2020;22(7):71.","journal-title":"Curr Oncol Rep"},{"issue":"12","key":"1240_CR37","doi-asserted-by":"publisher","first-page":"2897","DOI":"10.1038\/s41409-021-01428-1","volume":"56","author":"A Mishra","year":"2021","unstructured":"Mishra A, Pidala J, Thapa R, Betts BC, Fernandez H, Locke FL, et al. Objective and subjective physical function in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2021;56(12):2897\u2013903.","journal-title":"Bone Marrow Transplant."},{"issue":"1","key":"1240_CR38","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s00520-020-05485-y","volume":"29","author":"M Limbach","year":"2021","unstructured":"Limbach M, Kuehl R, Dreger P, Luft T, Rosenberger F, Kleindienst N, et al. Influencing factors of cardiorespiratory fitness in allogeneic stem cell transplant candidates prior to transplantation. Support Care Cancer. 2021;29(1):359\u201367.","journal-title":"Support Care Cancer"},{"issue":"4","key":"1240_CR39","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1002\/mus.24572","volume":"52","author":"MA Minetto","year":"2015","unstructured":"Minetto MA, Qaisar R, Agoni V, Motta G, Longa E, Miotti D, et al. Quantitative and qualitative adaptations of muscle fibers to glucocorticoids. Muscle Nerve. 2015;52(4):631\u20139.","journal-title":"Muscle Nerve"},{"issue":"8","key":"1240_CR40","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1007\/s00520-013-1778-7","volume":"21","author":"S Morishita","year":"2013","unstructured":"Morishita S, Kaida K, Yamauchi S, Sota K, Ishii S, Ikegame K, et al. Relationship between corticosteroid dose and declines in physical function among allogeneic hematopoietic stem cell transplantation patients. Support Care Cancer. 2013;21(8):2161\u20139.","journal-title":"Support Care Cancer"},{"issue":"4","key":"1240_CR41","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1007\/s00520-014-2425-7","volume":"23","author":"T Takekiyo","year":"2015","unstructured":"Takekiyo T, Dozono K, Mitsuishi T, Murayama Y, Maeda A, Nakano N, et al. Effect of exercise therapy on muscle mass and physical functioning in patients undergoing allogeneic hematopoietic stem cell transplantation. Support Care Cancer. 2015;23(4):985\u201392.","journal-title":"Support Care Cancer"},{"issue":"4","key":"1240_CR42","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1097\/PHM.0000000000001660","volume":"100","author":"A Ngo-Huang","year":"2021","unstructured":"Ngo-Huang A, Yadav R, Bansal S, Williams J, Wu J, Fu JB, et al. An exploratory study on physical function in stem cell transplant patients undergoing corticosteroid treatment for acute graft-versus-host-disease. Am J Phys Med Rehabil. 2021;100(4):402\u20136.","journal-title":"Am J Phys Med Rehabil"},{"issue":"4","key":"1240_CR43","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s00520-011-1156-2","volume":"20","author":"S Morishita","year":"2012","unstructured":"Morishita S, Kaida K, Ikegame K, Yoshihara S, Taniguchi K, Okada M, et al. Impaired physiological function and health-related QOL in patients before hematopoietic stem-cell transplantation. Support Care Cancer. 2012;20(4):821\u20139.","journal-title":"Support Care Cancer"},{"key":"1240_CR44","doi-asserted-by":"crossref","unstructured":"Inoue J, Kai M, Doi H, Okamura A, Yakushijin K, Makiura D, et al. Association between physical function and health-related quality of life in survivors of hematological malignancies undergoing hematopoietic stem cell transplantation. Trends Transplant.\u00a02020;14:1-5.","DOI":"10.15761\/TiT.1000289"},{"key":"1240_CR45","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1182\/blood-2020-134646","volume":"136","author":"E Mullane","year":"2020","unstructured":"Mullane E, Jones T, Voutsinas J, Wu QV, Loggers E, Fann J, et al. Patient-reported outcomes at time of CAR-T cell therapy. Blood. 2020;136:35\u20136.","journal-title":"Blood"},{"issue":"5","key":"1240_CR46","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1007\/s00520-018-4433-5","volume":"27","author":"A Ishikawa","year":"2019","unstructured":"Ishikawa A, Otaka Y, Kamisako M, Suzuki T, Miyata C, Tsuji T, et al. Factors affecting lower limb muscle strength and cardiopulmonary fitness after allogeneic hematopoietic stem cell transplantation. Support Care Cancer. 2019;27(5):1793\u2013800.","journal-title":"Support Care Cancer"},{"issue":"11","key":"1240_CR47","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1249\/MSS.0000000000002116","volume":"51","author":"KL Campbell","year":"2019","unstructured":"Campbell KL, Winters-Stone KM, Wiskemann J, May AM, Schwartz AL, Courneya KS, et al. Exercise guidelines for cancer survivors: consensus statement from International Multidisciplinary Roundtable. Med Sci Sports Exerc. 2019;51(11):2375\u201390.","journal-title":"Med Sci Sports Exerc"},{"issue":"7","key":"1240_CR48","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1249\/MSS.0b013e318213fefb","volume":"43","author":"CE Garber","year":"2011","unstructured":"Garber CE, Blissmer B, Deschenes MR, Franklin BA, Lamonte MJ, Lee IM, et al. American College of Sports Medicine position stand. Quantity and quality of exercise for developing and maintaining cardiorespiratory, musculoskeletal, and neuromotor fitness in apparently healthy adults: guidance for prescribing exercise. Med Sci Sports Exerc. 2011;43(7):1334\u201359.","journal-title":"Med Sci Sports Exerc"},{"issue":"5","key":"1240_CR49","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.amepre.2009.01.021","volume":"36","author":"SJ Marshall","year":"2009","unstructured":"Marshall SJ, Levy SS, Tudor-Locke CE, Kolkhorst FW, Wooten KM, Ji M, et al. Translating physical activity recommendations into a pedometer-based step goal: 3000 steps in 30 minutes. Am J Prev Med. 2009;36(5):410\u20135.","journal-title":"Am J Prev Med"},{"issue":"4","key":"1240_CR50","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.jsams.2009.03.002","volume":"12","author":"SC Hayes","year":"2009","unstructured":"Hayes SC, Spence RR, Galvao DA, Newton RU. Australian Association for Exercise and Sport Science position stand: optimising cancer outcomes through exercise. J Sci Med Sport. 2009;12(4):428\u201334.","journal-title":"J Sci Med Sport"},{"issue":"6","key":"1240_CR51","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/S1470-2045(09)70031-2","volume":"10","author":"LW Jones","year":"2009","unstructured":"Jones LW, Eves ND, Haykowsky M, Freedland SJ, Mackey JR. Exercise intolerance in cancer and the role of exercise therapy to reverse dysfunction. Lancet Oncol. 2009;10(6):598\u2013605.","journal-title":"Lancet Oncol"},{"issue":"5","key":"1240_CR52","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/nrclinonc.2012.27","volume":"9","author":"SG Lakoski","year":"2012","unstructured":"Lakoski SG, Eves ND, Douglas PS, Jones LW. Exercise rehabilitation in patients with cancer. Nat Rev Clin Oncol. 2012;9(5):288\u201396.","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"1240_CR53","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1249\/MSS.0000000000000498","volume":"47","author":"R Kuehl","year":"2015","unstructured":"Kuehl R, Scharhag-Rosenberger F, Schommer K, Schmidt ME, Dreger P, Huber G, et al. Exercise intensity classification in cancer patients undergoing allogeneic HCT. Med Sci Sports Exerc. 2015;47(5):889\u201395.","journal-title":"Med Sci Sports Exerc"},{"issue":"6","key":"1240_CR54","doi-asserted-by":"publisher","first-page":"e12922","DOI":"10.1111\/ecc.12922","volume":"27","author":"T Fukushima","year":"2018","unstructured":"Fukushima T, Nakano J, Ishii S, Natsuzako A, Sakamoto J, Okita M. Low-intensity exercise therapy with high frequency improves physical function and mental and physical symptoms in patients with haematological malignancies undergoing chemotherapy. Eur J Cancer Care (Engl). 2018;27(6):e12922.","journal-title":"Eur J Cancer Care (Engl)"},{"issue":"12","key":"1240_CR55","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.jtct.2021.09.002","volume":"27","author":"NA Szewczyk","year":"2021","unstructured":"Szewczyk NA, Ngo-Huang A, Soones TN, Adekoya LM, Fontillas RC, Ferguson JK, et al. Feasibility and implementation of a multimodal supportive care program to improve outcomes in older patients undergoing allogeneic stem cell transplantation. Transplant Cell Ther. 2021;27(12):1008\u201314.","journal-title":"Transplant Cell Ther."}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-022-01240-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-022-01240-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-022-01240-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T11:41:27Z","timestamp":1744198887000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-022-01240-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,10]]},"references-count":55,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["1240"],"URL":"https:\/\/doi.org\/10.1007\/s11912-022-01240-0","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,10]]},"assertion":[{"value":"7 February 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Obada Obaisi, Dr. Rhodora Fontillas, and Dr. An Ngo-Huang declare they have no financial interests. Dr. Krina Patel served on the advisory boards and received research funding from Janssen, Bristol Meyers Squibb; served on the advisory board for Arcellx and Pfizer; and completed clinical trials with Cellectis, Poseida, Takeda, and Prescisionbio.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}